How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,526 results for

Alpha Adrenergic Antagonist

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade

: Boehringer Ingelheim ClinicalTrials.gov Identifier: Other Study ID Numbers: 527.28 First Posted: September 19, 2014 Last Update Posted: September 19, 2014 Last Verified: September 2014 Additional relevant MeSH terms: Layout table for MeSH terms Hyperplasia Prostatic Hyperplasia Pathologic Processes Prostatic Diseases Genital Diseases, Male Adrenergic Agents Adrenergic Antagonists Adrenergic alpha-Antagonists Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects (...) Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2014 Clinical Trials

22. Importance of Alpha-adrenergic Receptor Subtypes in Regulating of Airways Tonus at Patients with Bronchial Asthma Full Text available with Trip Pro

Importance of Alpha-adrenergic Receptor Subtypes in Regulating of Airways Tonus at Patients with Bronchial Asthma In this work, effect of Tamsulosin hydrochloride as antagonist of alpha1A and alpha1B- adrenergic receptor and effect of Salbutamol as agonist of beta2- adrenergic receptor in patients with bronchial asthma and increased bronchial reactibility was studied.Parameters of the lung function are determined by Body plethysmography. Raw and ITGV were registered and specific resistance (...) (SRaw) was also calculated. Tamsulosin was administered in per os way as a preparation in the form of the capsules with a brand name of "Prolosin", producer: Niche Generics Limited, Hitchin, Herts.Results gained from this research show that blockage of alpha1A and alpha1B- adrenergic receptor with Tamsulosin hydrochloride (0.4 mg and 0.8 mg in per os way) has not changed significantly (p > 0.1) the bronchomotor tonus of tracheobronchial tree in comparison to the inhalation of Salbutamol as agonist

2014 Acta Informatica Medica

23. β2-Adrenergic Receptor-Mediated HIF-1α Upregulation Mediates Blood Brain Barrier Damage in Acute Cerebral Ischemia Full Text available with Trip Pro

was accompanied by suppressed occludin degradation and vascular endothelial growth factor (VEGF) mRNA upregulation. Interestingly, β2-adrenergic receptor (β2-AR) antagonist ICI 118551 attenuated ischemia-induced BBB damage by regulating HIF-1α expression. Double immunostaining showed that HIF-1α was upregulated in ischemic neurons but not in astrocytes andendothelial cells. Of note, HIF-1α inhibition with inhibitor YC-1 or siRNA significantly prevented OGD-induced VEGF upregulation as well as the secretion (...) β2-Adrenergic Receptor-Mediated HIF-1α Upregulation Mediates Blood Brain Barrier Damage in Acute Cerebral Ischemia Disruption of the blood brain barrier (BBB) within the thrombolytic time window is an antecedent event to intracerebral hemorrhage in ischemic stroke. Our recent studies showed that 2-h cerebral ischemia induced BBB damage in non-infarcted area and secreted matrix metalloproteinase-2 (MMP-2) accounted for this disruption. However, the factors that affect MMP-2 secretion

2017 Frontiers in molecular neuroscience

24. Adrenergic System in Islet Transplantation

Propranolol Phentolamine Adrenergic Agents Adrenergic beta-Antagonists Adrenergic Antagonists Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Vasodilator Agents Adrenergic alpha-Antagonists (...) Adrenergic System in Islet Transplantation Adrenergic System in Islet Transplantation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Adrenergic System in Islet Transplantation (Aim 1 Islets) The safety

2017 Clinical Trials

25. Beta Adrenergic Receptor

. Related Studies (from Trip Database) Ontology: Receptors, Adrenergic, beta-1 (C0001642) Definition (MSH) A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The adrenergic beta-1 receptors are equally sensitive to EPINEPHRINE and NOREPINEPHRINE and bind the agonist DOBUTAMINE and the antagonist METOPROLOL with high affinity. They are found in the HEART, juxtaglomerular cells, and in the central and peripheral nervous systems. Definition (NCI) Beta 1 adrenergic receptor protein (477 (...) adrenergic fibers, Beta Adrenergic Receptors are one of two major classes of adrenergic receptors (alpha and beta) based on their reactions to norepinephrine and epinephrine, on cellular effects of receptor activation, and on relative affinities and reactions to synthetic blocking or stimulating agents. Beta-adrenergic receptors respond to blocking agents such as propranolol and to activating agents such as isoproterenol. Beta-1 type receptors mediate lipolysis and increase cardiac rate and force

2018 FP Notebook

26. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia

-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology 2012; 61(5): 994-1003 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Adrenergic alpha-Antagonists /therapeutic use; Carbolines /therapeutic use; Drug Therapy, Combination; Erectile Dysfunction /drug therapy; Humans; Imidazoles /therapeutic use; Lower Urinary Tract Symptoms /drug (...) unknown. Limitations of the evidence (including small samples) mean the reliability of the findings remains unclear. Authors' objectives To assess the effects of phosphodiesterase type 5 inhibitors alone or in combination with alpha 1-adrenergic blockers on lower urinary tract symptoms associated with benign prostatic hyperplasia. Searching MEDLINE/PubMed, EMBASE and The Cochrane Library were searched up to September 2011 without language restrictions; search terms were reported. Relevant reference

2012 DARE.

27. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder

trial. JAMA 2006; 296: 2319-2328. Indexing Status Subject indexing assigned by NLM MeSH Adrenergic alpha-Antagonists /therapeutic use; Adult; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination /economics; Great Britain; Humans; Lower Urinary Tract Symptoms /drug therapy /etiology; Male; Middle Aged; Muscarinic Antagonists /therapeutic use; Prostatic Hyperplasia /complications; Quality of Life; State Medicine /economics; Urinary Bladder, Overactive /complications; Urination Disorders (...) Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder Estimating the quality-of-life impact and cost

2012 NHS Economic Evaluation Database.

28. Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

Flushing Alcohol-Related Disorders Skin Manifestations Signs and Symptoms Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Brimonidine Tartrate Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs (...) Treatment of Asian Flushing Syndrome With Topical Alpha Agonists Treatment of Asian Flushing Syndrome With Topical Alpha Agonists - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Treatment of Asian Flushing

2018 Clinical Trials

29. Alpha Adrenergic Receptor

Receptors (CNS) Inhibits Locus Ceruleus reflex arc Peripheral vasodilatation V. Medications: Alpha Adrenergics Alpha Adrenergic Agonist (Alpha Adrenergic Receptor) Alpha Non-Specific Alpha 1 Selective Methoxamine Alpha 2 Selective (See ) Alpha-methylnorepinephrine Alpha Receptor Antagonist Alpha Non-Specific Phentolamine Alpha 1 Selective (See ) Phenoxybenzamine Alpha 2 Selective Tolazoline Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search (...) Alpha Adrenergic Receptor Alpha Adrenergic Receptor Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Alpha Adrenergic Receptor Alpha

2015 FP Notebook

30. Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions

: January 11, 2019 Last Update Posted: January 29, 2019 Last Verified: January 2019 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Constipation Signs and Symptoms, Digestive Signs and Symptoms Alfuzosin Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms (...) Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2013 Clinical Trials

31. Regulation of rabbit myometrial alpha adrenergic receptors by estrogen and progesterone. Full Text available with Trip Pro

Regulation of rabbit myometrial alpha adrenergic receptors by estrogen and progesterone. The effects of estrogen and progesterone on uterine alpha-adrenergic receptors were investigated by direct receptor-binding studies. Immature female rabbits were primed with estrogen by intramuscular injections for 4 days. Other rabbits were primed with progesterone by injections of estrogen for 4 days followed by injections of progesterone for 4 days. The alpha adrenergic antagonist, [3H (...) ]dihydroergocryptine, was used to directly assess the number and affinity of alpha adrenergic receptors in membranes derived from estrogen-and progesterone-primed uteri. Membranes from estrogen-primed uteri contained 257 +/- 52 fmol of [3H]dihydroergocryptine-binding sites per mg protein whereas membranes from progesterone-primed uteri contained 83 +/- 11 fmol of of binding sites per mg protein. This reduction of alpha adrenergic receptor-binding sites by progesterone was statistically significant (P less than

1977 Journal of Clinical Investigation

32. N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver. Full Text available with Trip Pro

N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver. 1 The alpha-adrenoceptor of rat liver plasma membranes was studied by use of the specific alpha-antagonist [3H]-dihydroergocryptine ([3H]-DHEC). Catecholamines and adrenergic compounds displayed an order of affinity that is typical of an alpha-receptor. Nevertheless, protokylol, a potent beta-adrenoceptor agonist, exhibited a higher affinity than that of adrenaline for alpha-sites (...) . This result might be due to its bulky substituent on the amino group. 2 Further displacement experiments between [3H]-DHEC and four pairs of drugs differently substituted on the amino group (isoprenaline vs Cc-25, orciprenaline vs fenoterol, AH 3474 vs labetalol, pindolol vs hydroxybenzylpindolol) provided evidence that N-alkyl substitution decreased the affinity for alpha-sites (20 micromolar less than KD less than 200 micromolar), whereas an N-aralkyl one increased the affinity (0.17 micromloar less

1979 British journal of pharmacology

33. Alpha and beta adrenergic blockade in hypertension. (Abstract)

Alpha and beta adrenergic blockade in hypertension. 4112366 1972 07 08 2017 09 20 0140-6736 1 7758 1972 May 06 Lancet (London, England) Lancet Alpha and beta adrenergic blockade in hypertension. 979-82 Beilin L J LJ Juel-Jensen B E BE eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Adrenergic alpha-Antagonists 0 Adrenergic beta-Antagonists 0 Drug Combinations 0 Placebos 0TTZ664R7Z Phenoxybenzamine 9Y8NXQ24VQ Propranolol AIM IM S Adrenergic (...) alpha-Antagonists administration & dosage Adrenergic beta-Antagonists administration & dosage Adult Blood Pressure Body Weight Clinical Trials as Topic Drug Antagonism Drug Combinations Female Humans Hypertension drug therapy Hypotension, Orthostatic etiology Male Middle Aged Phenoxybenzamine administration & dosage adverse effects Physical Exertion Placebos Posture Propranolol administration & dosage adverse effects Pulse 72175671 1972 5 6 1972 5 6 0 1 1972 5 6 0 0 ppublish 4112366 S0140-6736(72

1972 Lancet (London, England) Controlled trial quality: uncertain

34. Alpha blockers v calcium blockers to increase spontaneous passage of renal calculi

Therapy (MET) – but you don’t know whether to prescribe alpha-adrenergic antagonists or calcium channel blockers. Search Strategy Ovid MEDLINE 1946 to Nov week 2 2012 and Embase 1980 to 2012 Week 46 via OVIDSP interface. [adrenergic alpha antagonist.mp OR alpha blocker$.mp. OR tamsulosin.mp. OR flomax.mp. OR alfuzosin.mp. OR doxazosin.mp. OR terazosin.mp. OR silodosin.mp. OR calcium antagonist$.mp. calcium channel blocker.mp. OR nifedipine.mp. OR nimodipine.mp. OR amlodipine.mp. OR felodipine.mp (...) : 17th April 2013 Status: Green (complete) Three Part Question In [adult patients with urinary calculi] is [treatment with alpha receptor blockers superior to treatment with calcium channel antagonists] at [increasing the speed and success of spontaneous stone passage]? Clinical Scenario A 51 year old presents to A&E with loin pain and macroscopic haematuria and a diagnosis of renal calculi is made. The patient’s pain is adequately controlled and the decision is discharge with Medical Expulsive

2013 BestBETS

35. Preoperative Alpha Blockade for Pheochromocytoma

-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Additional relevant MeSH terms: Layout table for MeSH terms Pheochromocytoma Paraganglioma Carotid Body Tumor Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Paraganglioma, Extra-Adrenal Doxazosin Phenoxybenzamine Antihypertensive Agents Adrenergic alpha-1 Receptor Antagonists (...) Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Vasodilator Agents

2017 Clinical Trials

36. Prophylactic Alpha-blockers in the Prevention of Urinary Retention Post Inguinal Hernia Repair

in and Exported from the U.S.: No Additional relevant MeSH terms: Layout table for MeSH terms Hernia Hernia, Inguinal Urinary Retention Pathological Conditions, Anatomical Hernia, Abdominal Urination Disorders Urologic Diseases Tamsulosin Adrenergic alpha-Antagonists Adrenergic alpha-1 Receptor Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents (...) have been demonstrated to be rich in alpha-1 adrenergic receptors. Our research idea is novel because there has been no prior prospective study conducted using alpha-blockers to reduce post-operative urinary retention in patients undergoing inguinal hernia repair. The proposed research is important as existing studies that sought to understand POUR have merely established the risks factors involved. Despite so, the incidence of POUR remains high and no studies to date have investigated the use

2017 Clinical Trials

37. Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia Full Text available with Trip Pro

100968571 1471-2490 0 Adrenergic alpha-Antagonists 0 Muscarinic Antagonists IM Adrenergic alpha-Antagonists administration & dosage economics Aged Drug Therapy, Combination Health Care Costs trends Health Resources economics statistics & numerical data Humans Lower Urinary Tract Symptoms drug therapy economics epidemiology Male Middle Aged Muscarinic Antagonists administration & dosage economics Prostatic Hyperplasia drug therapy economics epidemiology Retrospective Studies Spain epidemiology (...) Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia 28899370 2018 10 05 2018 12 02 1471-2490 17 1 2017 Sep 12 BMC urology BMC Urol Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia. 83 10.1186/s12894

2017 BMC urology

38. [Alpha-blockers as medical expulsive therapy for ureteral stones]. (Abstract)

, Deutschland. ger Journal Article Meta-Analysis Review Alpha-Blocker zur medikamentösen Expulsionstherapie für Harnleitersteine. Germany Urologe A 1304110 0340-2592 0 Adrenergic alpha-1 Receptor Antagonists IM Adolescent Adrenergic alpha-1 Receptor Antagonists administration & dosage Adult Aged Aged, 80 and over Comorbidity Hospitalization statistics & numerical data Humans Middle Aged Pain epidemiology prevention & control Prevalence Risk Factors Treatment Outcome Ureteral Calculi drug therapy (...) [Alpha-blockers as medical expulsive therapy for ureteral stones]. 27246474 2017 05 09 2018 11 13 1433-0563 55 6 2016 Jun Der Urologe. Ausg. A Urologe A [Alpha-blockers as medical expulsive therapy for ureteral stones]. 813-6 10.1007/s00120-016-0140-3 Schmidt S S UroEvidence@Deutsche Gesellschaft für Urologie, Kuno-Fischer-Str. 8, 14057, Berlin, Deutschland. schmidt@dgu.de. Miernik A A Department Chirurgie Klinik für Urologie, Universitätsklinikum Freiburg, Hugstetter Str. 55, 79106, Freiburg

2017 Der Urologe. Ausg. A

39. Alpha blockers in the management of ureteric lithiasis: A meta-analysis. Full Text available with Trip Pro

, was conducted using PubMed and Embase. All randomised trials comparing α-blocker monotherapy to placebo or standard therapy were included. Stone expulsion rate was the primary outcome measure. Secondary outcome measures were time to stone expulsion, analgesic usage and pain scores. Subgroup analyses assessed individual adrenergic antagonists and variations in standard therapy. Sensitivity analysis was based on stone location, stone size, Cochrane Risk of Bias score and study protocol. Summary effects were (...) Alpha blockers in the management of ureteric lithiasis: A meta-analysis. Effective medical expulsion for ureteric stones with α-blockers offers numerous advantages over surgical alternatives. However, its effectiveness remains uncertain and with the publication of new trial data, the available evidence requires reappraisal.The aim of this study was to assess the efficacy of α-blockers the management of ureteric lithiasis.A systematic review of the literature, with predefined search criteria

2017 International journal of clinical practice

40. Pelvic floor muscle therapy or alpha-blocking agents for treatment of men with lower urinary tract symptoms: An exploratory randomized controlled trial. (Abstract)

of Groningen, Groningen, the Netherlands. Blanker Marco H MH Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Dekker Janny H JH Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. eng Journal Article 2017 03 22 Australia Int J Urol 9440237 0919-8172 Int J Urol. 2017 Jun;24(6):475 28503766 adrenergic alpha-1 receptor antagonists behavior therapy lower urinary tract (...) Pelvic floor muscle therapy or alpha-blocking agents for treatment of men with lower urinary tract symptoms: An exploratory randomized controlled trial. 28332234 2018 12 31 1442-2042 24 6 2017 06 International journal of urology : official journal of the Japanese Urological Association Int. J. Urol. Pelvic floor muscle therapy or alpha-blocking agents for treatment of men with lower urinary tract symptoms: An exploratory randomized controlled trial. 473-474 10.1111/iju.13339 Hut Jan J

2017 International journal of urology : official journal of the Japanese Urological Association Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>